AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

One of the primary features of Alzheimer’s is the buildup of amyloid-beta plaques in the brain, which are thought to disrupt ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

The clumping of amyloid beta in the brain to form plaques is one the hallmarks of AD, and the 'amyloid hypothesis' suggests they are a primary driver for the neurodegeneration seen in the disease.

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

is recommending the diagnosis of AD be limited to individuals with mild cognitive impairment or dementia and not be applied ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

Korea University Guro Hospital has opened the Alzheimer's Prevention Center (Center Director Kang Sung-hoon).The Alzheimer's ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

Dr. Schacterle is a highly regarded leader who has successfully led global regulatory and quality activities across multiple neurologic and psychiatric therapeutic areas and all stages of development, ...